To view a list of available clinical trials, select a type of cancer below. You will get a general overview of the trial, the trial number, and a link to clinicaltrials.gov for the most complete information.
The OHC Clinical Trials program has 27 clinical research team members who are engaged in the passionate search for innovative treatments. OHC trials are offered at five of our offices right here in the Greater Cincinnati area. This easy access to national trials offers our patients early access to the latest in leading edge treatments without having to leave the Cincinnati community.
Cholangiocarcinoma - QBGJ398-301
A Phase 3, Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF
Learn MoreCholangiocarcinoma - 42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (Waterhouse)
Learn MoreUrothelial Cancer - BLC3001
A Phase 3, study of Erdafitinib compared with Docetaxel or Pembrolizumab in subjects with advanced urothelial cancer and selected FGFR gene aberrations
Learn MoreUrothelial Cancer - 42756493BLC0002
Observational, Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations.(Waterhouse)
Learn MoreUrothelial Cancer - QBGJ398-302
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations
Learn MoreUrothelial Cancer - 42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (Waterhouse)
Learn MoreUrothelial Cancer - SGN22E-002
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Learn MoreUrothelial Cancer - 516-003
A Phase 2 Study of Sitravatinib in Combination with PD-L (1) Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
Learn MoreBrain Cancer - 42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (Waterhouse)
Learn MoreBreast Cancer - 3379428
Phase 1/2, trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer (Lang)
Learn MoreBreast Cancer - FLEX Registry
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry)
Learn MoreBreast Cancer - 2017-0758
Observational, A Prospective Observational Study Comparing the Effectiveness of Neulasta® (Pegfilgrastim) Onpro® kit to Other Physician Choice Options for Prophylaxis of Febrile Neutropenia in Subjects with Non-Myeloid Malignancies at High Risk for Febrile Neutropenia (Ward)
Learn MoreBreast Cancer - CT7001-001
A Phase 1/2, Study of CT7001 in Combination with Fulvestrant in Patients with Metastatic or Locally Advanced Hormone-Receptor Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (Ward)
Learn MoreBreast Cancer - SGNTUC-016
Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)
Learn MoreFGFR mutated Breast Cancer - INCB 54828-207
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations
Learn MoreFGFR mutated Breast Cancer - 42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (Waterhouse)
Learn MoreFGFR mutated Colorectal Cancer - INCB 54828-207
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations
Learn MoreFGFR mutated Colorectal Cancer - 42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (Waterhouse)
Learn MoreKRAS G12C mutated Colorectal Cancer - 849-001
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Learn MoreHER2+ metastatic Colorectal Cancer - ACCRU-GI-1617, SGNTUC-017
A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer
Learn MoreEsophageal Squamous Cell Carcinoma - CIBI308A301
A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)
Learn MoreCervical - AK104-201-AU
A Phase 2, multicenter, single-arm, open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (Chua)
Learn MoreOvarian, Peritoneal, Fallopian - MK7339-001/ENGOT-ov43/GOG-3036
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (Chua)
Learn MoreOvarian - SLS17-201
A Phase 1/2, Study of Galinpepimut-S in combination with Pembrolizumab (MK-3475) in patients with selected advanced cancers (Ward)
Learn MoreFGFR mutated solid tumor - INCB 54828-207
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations
Learn MoreCervical, Endometrial, Ovarian - CPI-006-001
A Phase 1/1b, Multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent or in combination with Ciforadenant, with Pembrolizumab, and with Ciforadenant plus Pembrolizumab in adult subjects with advanced cancers (Waterhouse)
Learn MoreOvarian, Peritoneal, Fallopian - IMGN853-0416
Phase 3, Study of Mirvetuximab Soravtansine vs Investigators' Choice of Chemotherapy in Platinum-Resistant, Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Learn MoreFGFR mutated solid tumor - 42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (Waterhouse)
Learn MoreSquamous Cell Carcinoma - 42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (Waterhouse)
Learn MoreSquamous Cell Carcinoma - CPI-006-001
A Phase 1/1b Multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent or in combination with Ciforadenant, with Pembrolizumab, and with Ciforadenant plus Pembrolizumab in adult subjects with advanced cancers (Waterhouse)
Learn MoreGraft Versus Host Disease - INCB 39110-309
A Phase 3, Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309).(Essell)
Learn MoreNon-Hodgkin's Lymphoma - CTL019H2301 (BELINDA)
CAR-T - Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (Essell)
Learn MoreMultiple Myeloma - 54767414MMY3021
A Randomized Study of Daratumumab Plus Lenalidomide Alone as A maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (Faber)
Learn MoreAcute Myeloid Leukemia (AML) - PTC299-HEM-001-LEU
Phase 1b, Study of PTC299 in Relapsed/Refractory Acute Leukemias. (Broun)
Learn MoreAcute Myeloid Leukemia (AML) - M19-072
A Phase 3b, Single-Arm, Multicenter Open-Label Study of sponsor provided Venetoclax in Combination with Azacitidine (SOC) or Decitabine (SOC) in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy. (Broun)
Learn MoreChronic Myeloid Leukemia (CML) - CA180653
Observational, No drug provided. Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-line Therapy in the United States. (Essell)
Learn MoreNon Small Cell Lung Cancer - 2017-0758
Observational, A Prospective Observational Study Comparing the Effectiveness of Neulasta® (Pegfilgrastim) Onpro® kit to Other Physician Choice Options for Prophylaxis of Febrile Neutropenia in Subjects with Non-Myeloid Malignancies at High Risk for Febrile Neutropenia (Ward)
Learn MoreNon Small Cell Lung Cancer - Brigatinib-3001
A Phase 3, Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib
Learn MoreNon Small Cell Lung Cancer - BLU-667-1101
A Phase 1, Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101) RET Mutation or Rearrangement.
Learn MoreNon Small Cell Lung Cancer - 516-005
A Phase 3, Randomized Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy (Waterhouse)
Learn MoreNon Small Cell Lung Cancer - INCB 54828-207
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations
Learn MoreNon Small Cell Lung Cancer - CPI-006-001
A Phase 1/1b, Multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent or in combination with Ciforadenant, with Pembrolizumab, and with Ciforadenant plus Pembrolizumab in adult subjects with advanced cancers (Waterhouse)
Learn MoreNon Small Cell Lung Cancer - CA209-73L
A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (Waterhouse)
Learn MoreNon Small Cell Lung Cancer - 20190009
A Phase 3 Multicenter, Randomized , Open Label, Active-controlled, Study of AMG 510 versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.g12C (Waterhouse)
Learn MoreNon Small Cell Lung Cancer - GO41717
A Phase 3. Double-Blinded, Placebo-controlled study of Tiragolumab, an anti-TIGIT antibody, in combination with Atezolizumab compared with Placebo in combination with Atezolizumab in patients with previously untreated locally advanced unresectable or metastatic PD-L1 selected non-small cell lung cancer (Waterhouse)
Learn MoreNon Small Cell Lung Cancer - 42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (Waterhouse)
Learn MoreNon Small Cell Lung Cancer - BLU-667-2303
A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer
Learn MoreNon Small Cell Lung Cancer - CX-839-014 (KEAPSAKE)
A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer
Learn MoreNon Small Cell Lung Cancer - 20190294
Observational, A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Non-Small Cell Lung Cancer (Waterhouse)
Learn MoreNon Small Cell Lung Cancer - 849-001
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Learn MoreHodgkin's Lymphoma - SGN35-015
a Phase 2, Therapeutic. Brentuximab Vedotin provided. A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults age 60 and Above
Learn MoreNon-Hodgkin's Lymphoma (Follicular) - PCYC-1141-CA
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma (Islas-Ohlmayer)
Learn MoreNon-Hodgkin's Lymphoma - 17006
CAR-T - A Phase 2, study of JCAR017 as Second-Line Therapy in Patients with Aggressive B-cell NHL (Essell)
Learn MoreHodgkin's Lymphoma - SGN35-027
A Phase 2, Multi-Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma subjects
Learn MoreNon-Hodgkin's Lymphoma - 17007
CAR-T - A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory B-cell Non-Hodgkin Lymphoma in the Outpatient Setting. (Essell)
Learn MoreNon-Hodgkin's Lymphoma - CTL019H2301 (BELINDA)
CAR-T - Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (Essell)
Learn MoreNon-Hodgkin's Lymphoma - BAY 88-8223 / 19781
An open-label, multicenter, Phase 1/2 study of radium-223 dichloride in combination with pembrolizumab in participants with stage IV non-small cell lung cancer (Fried)
Learn MoreNon-Hodgkin's Lymphoma - GO41036
A Phase 1a/1b, Open-label, multicenter study evaluating the safety of Tiragolumab as a single agent and in combination with Daratumumab in patients with relapsed or refractory Multiple Myeloma, and as a single agent and in combination with Rituximab in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma. (Faber)
Learn MoreNon-Hodgkin's Lymphoma - CPI-006-001
A Phase 1/1b, Multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent or in combination with Ciforadenant, with Pembrolizumab, and with Ciforadenant plus Pembrolizumab in adult subjects with advanced cancers (Waterhouse)
Learn MoreMyelofibrosis - PAC203
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL)
Learn MoreMultiple Myeloma - 20180117
An Open-label, Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma with Carfilzomib, Pomalidomide, and Dexamethasone (KPd). (Faber)
Learn MoreMultiple Myeloma - 207495
A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone i9n Participants with Relapsed/Refractory Multiple Myeloma (Faber)
Learn MoreMultiple Myeloma - INCB 01158-206
A Phase 1/2, Randomized Open-Label study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma. (Faber)
Learn MoreMultiple Myeloma - 20180015
A Phase 3, Randomized, Open-Label, Phase 3 Study comparing once-weekly vs Twice-weekly Carfilzomib in combination with Lenalidomide and Dexamethasone in subjects with relapsed or refractory Multiple Myeloma (Faber)
Learn MoreMultiple Myeloma - GO41036
A Phase 1a/1b, Open-label, multicenter study evaluating the safety of Tiragolumab as a single agent and in combination with Daratumumab in patients with relapsed or refractory Multiple Myeloma, and as a single agent and in combination with Rituximab in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma. (Faber)
Learn MoreMultiple Myeloma - 54767414MMY3021
A Randomized Study of Daratumumab Plus Lenalidomide Alone as A maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (Faber)
Learn MoreMetastatic Castration-resistant Prostate Cancer - CO-338 063
A Phase 3, Therapeutic. Atezolizumab provided. A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (TRITON3).
Learn MoreMetastatic Castration-resistant Prostate Cancer - 2017-0758
Observational, A Prospective Observational Study Comparing the Effectiveness of Neulasta® (Pegfilgrastim) Onpro® kit to Other Physician Choice Options for Prophylaxis of Febrile Neutropenia in Subjects with Non-Myeloid Malignancies at High Risk for Febrile Neutropenia (Ward)
Learn MoreMetastatic Castration-resistant Prostate Cancer - i3Y-MC-JPCM
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer
Learn MoreMetastatic Castration-resistant Prostate Cancer - INCB 54828-207
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Learn MoreMetastatic Castration-resistant Prostate Cancer - CPI-006-001
A Phase 1/1b, Multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent or in combination with Ciforadenant, with Pembrolizumab, and with Ciforadenant plus Pembrolizumab in adult subjects with advanced cancers (Waterhouse)
Learn MoreMetastatic Castration-resistant Prostate Cancer - 42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (Waterhouse)
Learn MoreMetastatic Castration-resistant Prostate Cancer - 64091742PCR2002
A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Learn MoreMetastatic Prostate Cancer - 64091742PCR3001
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer
Learn MoreClear Cell Renal Cell Carcinoma - CPI-006-001
A Phase 1/1b, Multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent or in combination with Ciforadenant, with Pembrolizumab, and with Ciforadenant plus Pembrolizumab in adult subjects with advanced cancers (Waterhouse)
Learn MoreClear Cell Renal Cell Carcinoma - GU-MK-6482-005
A Phase 3, Open-label, Randomized Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies
Learn MoreClear Cell Renal Cell Carcinoma - 42756493CAN2002
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (Waterhouse)
Learn More